|Mr. Robert J. Gibson||Vice Chairman, Sec. & Treasurer||180k||N/A||N/A|
|Mr. Ira Scott Greenspan||Sr. Advisor & Director||180k||N/A||1959|
|Dr. Alan M. Horsager Ph.D.||Pres||N/A||N/A||N/A|
|Mr. Daniel J. Politzer C.F.A.||CFO & COO||N/A||N/A||1969|
|Mr. David Silberg||Sr. Advisor||N/A||N/A||1949|
|Alan D. Horsager Ph.D.||Pres?of?Immuno-Oncology and Pres & CEO of Olimmune Inc.||N/A||N/A||1973|
Scopus BioPharma Inc., a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Its lead development programs are immuno-oncology gene therapy for the treatment of various cancers, which include CO-sTiRNA, a STAT3 inhibitor gene therapy that drives tumor cell growth and anti-tumor immune suppression; and MRI-1867, a cannabinoid-1 receptor inverse agonist and inhibitor of inducible nitric oxide synthase for the treatment of systemic sclerosis. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
Scopus BioPharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.